mRNA Process and Cost Modeling: A Tool to Optimize Process Development

by Carole Inglevert | September 4, 2023

mRNA-cost-modelling-banner_LI_1200x628

mRNA technology has proven to enable rapid drug development. mRNA is an attractive modality to work with because of its relative simplicity compared to other biologics; it is wholly synthetic and does not require cellular materials. Demand for mRNA-based medicine production in lower income countries continues to increase, as do investments in prophylactic and therapeutic indications such as infectious diseases and cancer. We developed a cost-model to compare all modalities such as virus-like particles, viral vectors, and mRNA, which enables decision making on production scale and plant sizing. This poster highlights several aspects of the cost-modelling work, such as the distribution of costs, cost per vaccine dose, and proposes various scenarios to meet forecasted mRNA demand.

Read Now!

Carole Inglevert
Marketing Communication Manager

Related Posts

Starting your journey into manufacturing – choosing a cell line development provider

One of the biggest decisions which any company developing biological medicines makes is to move forward to the manufacture of their product. …

Covid-19 Impact on Bioprocessing: PART 1 Accelerating Trends

The views and opinions expressed in this blog / article are those of the authors and do not…

Covid-19 Impact on Bioprocessing: PART 2 Fears to Be Addressed due to Covid-19

The views and opinions expressed in this blog / article are those of the authors and do not…

Covid-19 Impact on Bioprocessing: PART 3 Long-term Changes Resulting from the Pandemic

The views and opinions expressed in this blog / article are those of the authors and do not…

Scroll to Top